Genomic predictors for treatment of late stage prostate cancer

por Shevrin, Daniel H
Publicado 2016

Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research

por Penson, David F, Lin, Daniel W, Karsh, Lawrence, Quinn, David I, Shevrin, Daniel H, Shore, Neal, Symanowski, James T, Brown, Bruce, Forer, David, Wong, Elaine K, Flanders, Scott C
Publicado 2016

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial

por Morris, Michael J., Loriot, Yohann, Sweeney, Christopher J., Fizazi, Karim, Ryan, Charles J., Shevrin, Daniel H., Antonarakis, Emmanuel S., Pandit-Taskar, Neeta, Deandreis, Désirée, Jacene, Heather A., Vesselle, Hubert, Petrenciuc, Oana, Lu, Cindy, Carrasquillo, Jorge A., Higano, Celestia S.
Publicado 2019

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

por Autio, Karen A., Antonarakis, Emmanuel S., Mayer, Tina M., Shevrin, Daniel H., Stein, Mark N., Vaishampayan, Ulka N., Morris, Michael J., Slovin, Susan F., Heath, Elisabeth I., Tagawa, Scott T., Rathkopf, Dana E., Milowsky, Matthew I., Harrison, Michael R., Beer, Tomasz M., Balar, Arjun V., Armstrong, Andrew J., George, Daniel J., Paller, Channing J., Apollo, Arlyn, Danila, Daniel C., Graff, Julie N., Nordquist, Luke, Dayan Cohn, Erica S., Tse, Kin, Schreiber, Nicole A., Heller, Glenn, Scher, Howard I.
Publicado 2021